Delisting Strategies in Highly Sensitised Kidney Transplant Candidates

Clicks: 14
ID: 331428
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #136 of 152 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 152 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
HLA antigen delisting has recently emerged as a new strategy to expand transplant opportunities in the population of broadly sensitised patients who have poor chance to receive a transplant offer through allocation systems due to present donor specific anti-HLA antibodies (DSA). Delisting involves removing selected HLA antigens from the unacceptable antigen list when are considered less immunogenic and/or the corresponding antibodies are considered lower risk, thereby increasing access to transplant offers. Current approaches recommend a stepwise strategy, initially targeting lower-risk antibodies and progressively considering higher-risk incompatibilities when transplantation is otherwise unlikely. However, transplantation in the presence of pre-existing DSA remains associated with increased risk of antibody-mediated rejection and inferior graft outcomes, requiring careful patient selection, multidisciplinary management, and close post-transplant monitoring. As definitions, eligibility criteria, and implementation of delisting strategies differ substantially among centres and countries, nephrologists working within multidisciplinary teams must interpret complex immunological information and participate in organ offer decisions for highly sensitised patients. The absence of standardised definitions and uniform immunological thresholds further complicates decision-making and highlights the need for practical guidance in balancing timely transplantation against long-term graft outcomes. This review provides practical tools for understanding delisting strategies and clinical decision-making by summarising current guidelines, clinical outcomes, and desensitisation protocols to support evidence-based transplantation decisions.
Reference Key
openalex_W7220676711 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marta D'Angelo, Ivan Zahrádka, Katerina Jaklova, Umberto Maggiore, Ondrej Viklicky
Are you one of these authors? Claim your profile
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag229
URL
https://doi.org/10.1093/ndt/gfag229
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.